Overview

A Study of SBT6050 Alone and in Combination With PD-1 Inhibitors in Subjects With Advanced HER2 Expressing Solid Tumors

Status:
Recruiting
Trial end date:
2024-08-01
Target enrollment:
Participant gender:
Summary
A first-in-human (FIH) study using SBT6050 and SBT6050 in combination with PD-1 inhibitors in HER2 expressing or amplified advanced malignancies
Phase:
Phase 1
Details
Lead Sponsor:
Silverback Therapeutics
Treatments:
Cemiplimab
Pembrolizumab